FIG. 2.
Liver immunohistochemistry. (a) Fumarylacetoacetate hydrolase positive (FAH+) staining from adult Fah+/+ control mouse; (b) FAH− staining from adult Fah−/− control mouse; (c) FAH stain on adult Fah−/− mouse treated with AAV, (d) AAV + vanillin, (e) AAV + bortezomib, or (f) AAV + vanillin + bortezomib; (g) hematoxylin and eosin (H&E) stain on adult Fah−/− mouse treated with vanillin; (h) H&E stain on adult Fah−/− mouse treated with bortezomib; (i) FAH stain on adult Fah−/− serial transplant recipients; (j) FAH stain on Fah−/−Ku70+/+ neonate treated with AAV; (k) FAH stain on Fah−/−Ku70+/− neonate treated with AAV; (l) FAH stain on Fah−/−Ku70−/− neonate treated with AAV. Scale bar=10 μm.
